THERAPEUTIC OPTIONS IN PREVENTING UTEROPLACENTAL UNIT HYPOXEMIA
A miscarriage is primarily defined as an unintentional loss of pregnancy before the 20th week of gestation. Both the practice and theory show that pregnancy losses up to the 10th week of gestation may, besides many other gynecological and microbiological causes, also be brought down to the existence of some of the acquired thrombophilia such as antiphospholipid syndrome. Numerous studies have been conducted to examine the efficiency of therapy administration to prevent adverse outcomes of pregnancy. Hereditary thrombophilia are more connected with adverce pregnancy outcomes.
Pasquier E, de Saint Martin L, Bohec C, Chauleur C, Bretelle F, Marhic G, et al, Endoxaparin for preventing of enexplained recurrent miscarriage: a multicenter randomized double blind placebo controlled trial, Blood. 2015; 125 (14): 2200-5.
Kaandorp SP, Goddijn M, Van der Post JA, Hutten BA, Verhoeve HR, Hamulyák K, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Eng J Med. 2010; 362 (17): 1586-96.
Clark P, Walker ID, Langhorne P, Crichton L, Thomson A, Greaves M, et al. Scottish Pregnancy Intervention Study SPIN collaborators. SPIN Scottish Pregnancy Intrevention study: a multicenter randomized controlled trial of low molecular weight heparin and low dose aspirin in women with recurrent miscarriage. Blood. 2010; 155 (21): 4162- 7.
Visser J, Ulandeer VM, Helmerhorst FM, Lampinen K, Morin-Papunen L, Bloemenkamp KW, et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thromb Haemost. 2011; 105 (2): 295-301.
Bouvier S, Cochery-Nouvellon É, Lavigne-Lissalde G, Mercier É, Fabbro-Peray P, Balducchi JP, et al. Comparative incidence of pregnancy outcomes in thrombophilia-positive women from the NOH-APS observational study. Blood. 2014; 123(3):414-21.
Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, et al. Thrombophilia in pregnancy: a systematic review. Br J haematol. 2006;132(2):171-96.
D’ippolito S, Di Nicuolo F, Marana R, Castellani R, Stinson J, Tersigni C, et al. Emerging non anticoagulant role of low molecular weight heparins on extravillous trophoblast functions and on heparin blinding epidermal growth factor and cystein rich angiogenic inducer 61 expression. Fertil Steril. 2012; 98 (4) 1028-36. e1-2.
Suga N, Sugimura M, Koshiishi T, Yorifuji T, Makino S, Takeda S. Heparin/heparin sulfate /CD44-v3 enhances cell migration in term placenta derived immortalized human trophoblastic cells. Biol Reprod.2012; 86 (5): 134, 1-8.
Ball E, Bulmer JN, Aysis S, Lyall F, Robson SC. Late sporadic miscarriage is associated with abnormalities in spiral artery transformation and trophoblast invasion. J Pathol. 2006; 208(4): 535-42.
Ball E, Robson SC, Ayis S, LyallF, Bulmer JN, Early embriotic demise: no evidence of abnormal spiral artery transformation or trophoblast invasion. J Pathol. 2006; 208 (4): 528-34.
Schwenke M, Knöfler M, Velicky P, Weimar CH, Kruse M, Samalecos A, et al. Control of human endometrial stromal cell motility by PDGF-BB, HB-EGF and trophoblastic secreted factors. PloS ONE. 2013; 8 (1): e 54336.
Tormene D, Grandone E, De Stefano V, Tosetto A, Palareti G, Margaglione M, et al. Obstetrics complicationsand pregnancy-related venous thromboembolism: the effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation. Thromb Haemost. 2012; 107(3): 477-84.
de Vries JI, van Pampus MG, Hague WM, Beyemer PD, Joosten JH; FRUIT Investigators. Low molecular weight heparin added to aspirin in the prevention of recurrent early onset preeclampsia in women with inheritable thrombophilia: the FRUIZ-RCT. J Thromb Haemost. 2012; 10(1): 64-72.
Bates SM, Greer IA,Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence Based Clinical practice Guideline. Chest. 2012; 141 (2 Supp): e691S-e736S.
Aracic N, Roje D, Jakus IA, Bakotin M, Stefanovic V. The Impact of inherited thrombophilia types and low molecular weight heparin treatment on pregnancy complications in women with previous adverse outcome, Yonsei Med J. 2016; 57 (5): 1230-5.
Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med. 2007;167(5):497-501.
Foka ZJ, Lambropoulos AF, Saravelos H, Karas GB, Karavida A, Agorastos T, et al. Factor V Leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod. 2000;15(2):458-62.
Kosmas IP, Tatsioni A, Ioannidis JP. Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertension. 2004;22(9):1655-62.
Chen Z, Xu F, Wei Y, Liu F, Qi H. Angiotensin converting enzyme insertion/ deletion polymorphism and risk of pregnancy hypertensive disorders: a meta-analysis. J Renin Angiotensin Aldosterone Syst. 2012;13(1):184-95.
Wu X, Zhao L, Zhu H, He D, Tang W, Luo Y. Association between the MTHFR C677T polymorphism and recurrent pregnancy loss: a meta-analysis. Genet Test Mol Biomarkers. 2012;16(7):806-11.
Subrt I, Ulcova-Gallova Z, Cerna M, Hejnalova M, Slovanova J, Bibkova K, et al. Recurrent pregnancy loss, plasminogen activator inhibitor- 1 (-675) 4G/5G polymorphism and antiphospholipid antibodies in Czech women. Am J Reprod Immunol. 2013;70(1):54-8.
Buchholz T, Lohse P, Rogenhofer N, Kosian E, Pihusch R, Thaler CJ. Polymorphisms in the ACE and PAI-1 genes are associated with recurrent spontaneous miscarriages. Hum Reprod. 2003;18(11):2473-7.
Fatini C, Gensini F, Battaglini B, Prisco D, Cellai AP, Fedi S, et al. Angiotensin-converting enzyme DD genotype, angiotensin type 1 receptor CC genotype, and hyperhomocysteinemia increase first-trimester fetal-loss susceptibility. Blood Coagul Fibrinolysis. 2000;11(7):657-62.
Yang C, Fangfang W, Jie L, Yanlong Y, Jie W, Xuefei L, et al. Angiotensin- converting enzyme insertion/deletion (I/D) polymorphisms and recurrent pregnancy loss: a meta-analysis. J Assist Reprod Genet. 2012;29(11):1167-73.
Said JM, Tsui R, Borg AJ, Higgins JR, Moses EK, Walker SP, et al. The PAI-1 4G/5G polymorphism is not associated with an increased risk of adverse pregnancy outcome in asymptomatic nulliparous women. J Thromb Haemost. 2012;10(5):881-6.
Aracic N, Roje D, Drmic Hofman I, Capkun V, Stefanovic V. Low molecular weight heparin treatment and impact of inherited thrombophilia type in pregnancies with previous adverse outcome. J Maternal Fetal Neonatal Med. 2015;28(3):306-10.
Langer R, Schreyer P, Bukovsky I, Caspi E. Adjuvant anticoagulant therapy inrepeated fetal loss. Harefuah 1980;99(3-4):65–7.
Di Simone N, Caliandro D, Castellani R, Ferrazzani S, De CS, Caruso A. Lowmolecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Hum Reprod. 1999;14(2):489–95.
Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood. 2009;114(12):2367–74.
Cohn DM, Goddijn M, Middeldorp S, Korevaar JC, Dawood F, Farquharson RG. Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy. J Thromb Haemost. 2010;8(10):2208–13.
Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol. 2010;115(6):1256–62.
Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005; (2):CD002859.
Alalaf S. Bemiparin versus low dose aspirin for management of recurrent earlypregnancy losses due to antiphospholipid antibody syndrome. Arch Gynecol Obstet. 2012;285(3):641–7.
de Jong PG, Goddijn M, Middeldorp S.. Antithrombotic therapy for pregnancy loss. Hum Reprod Update. 2013;19(6):656-73.
- There are currently no refbacks.
Copyright (c) 2018 Stefan Dugalic, Milos Petronijević
This work is licensed under a Creative Commons Attribution 4.0 International License.